MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Charles River Laboratories International Inc

Suletud

SektorTervishoid

145.79 -3.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

145.27

Max

151.11

Põhinäitajad

By Trading Economics

Sissetulek

-284M

-214M

Müük

-7.2M

1B

P/E

Sektori keskmine

752.6

73.239

Aktsiakasum

2.66

Kasumimarginaal

-21.32

Töötajad

18,700

EBITDA

-296M

-86M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+16.06% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-476M

8B

Eelmine avamishind

148.89

Eelmine sulgemishind

145.79

Uudiste sentiment

By Acuity

79%

21%

355 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Charles River Laboratories International Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. aug 2024, 10:30 UTC

Peamised uudised

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Charles River Laboratories International Inc Prognoos

Hinnasiht

By TipRanks

16.06% tõus

12 kuu keskmine prognoos

Keskmine 174.69 USD  16.06%

Kõrge 188 USD

Madal 155 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Charles River Laboratories International Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

0

Osta

14

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 159.08Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

355 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.